Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Piper Jaffray Downgrades Quidel to Neutral

Piper Jaffray Downgrades Quidel to Neutral

Dec 19, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Piper Jaffray has downgraded shares of Quidel to a Neutral rating from Overweight, citing the "limited upside" the company is likely to see in the 2016-2017 flu season.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

What's Popular?

In Molecular Diagnostics

  1. FDA Releases Reference Panel for Coronavirus Test Developers

  2. Congress Introduces Bipartisan Bills to Improve Access to SARS-CoV-2 Testing

  3. AACC Sends Testing Recommendations to Senate For SARS-CoV-2 Relief Bill

  4. Ginkgo Bioworks Nabs $70M Investment from Illumina, Others to Build Coronavirus NGS Testing

  5. Illumina, Genomic Medicine Sweden to Evaluate Sequencing-Based Leukemia Diagnostics

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.